Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aztreonam inhalation - Gilead Sciences

Drug Profile

Aztreonam inhalation - Gilead Sciences

Alternative Names: AI - Gilead; AZLI; Aztreonam lysine; Cayston; Corus 1020; GS-9268

Latest Information Update: 28 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antibacterials; Monobactams; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Phase III Bronchiectasis
  • Discontinued Burkholderia infections

Most Recent Events

  • 28 Apr 2023 Gilead Sciences initiates a phase II VitalBE trial in Bronchiectasis (Inhalation, Aerosol) (NCT03696290)
  • 27 Apr 2023 Phase-III clinical trials in Bronchiectasis (Non-cystic fibrosis-related) in United Kingdom (Inhalation)
  • 18 Mar 2023 Health Canada announces recall of two lots (032168 and 033357) of aztreonam inhalation (Cayston®) in Canada by Gilead Sciences, due to the potential of cracked glass vials in the lots
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top